X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MOR202 (felzartamab) is an investigational therapeutic human monoclonal antibody directed against CD38, a protein expressed on mature plasma cells. It is being evaluated for the treatment of antibody-mediated rejection (amr) in kidney transplant recipients.
Lead Product(s): Felzartamab
Therapeutic Area: Immunology Product Name: MOR202
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
The net proceeds will be used to advance MOR202 (felzartamab), a monoclonal antibody targeting CD38, through clinical readouts in multiple indications and preparation for registrational studies.
Lead Product(s): Felzartamab
Therapeutic Area: Nephrology Product Name: MOR202
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alpha Wave Global
Deal Size: $95.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 04, 2024
Details:
MOR 202 (felzartamab) is a monoclonal antibody directed against CD38, it has the potential to deplete CD38+ plasma cells while leaving other functionally important plasma cells intact. it is under phase 2 clinical development for the treatment of PMN.
Lead Product(s): Felzartamab
Therapeutic Area: Nephrology Product Name: MOR202
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
HIB210 is an investigational therapeutic human monoclonal antibody directed against complement factor C5a receptor 1 (C5aR1). C5aR1 is responsible for guiding and activating myeloid cells and is highly expressed on neutrophils, monocytes and macrophages.
Lead Product(s): HIB210
Therapeutic Area: Immunology Product Name: HIB210
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
MOR202 (felzartamab) is human monoclonal antibody directed against CD38, a protein expressed on mature plasma cells. In PMN, CD38+long-lived plasma cells drive pathogenic antibody production, contributing to functional damage to the glomeruli in the kidney.
Lead Product(s): Felzartamab
Therapeutic Area: Nephrology Product Name: MOR202
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
MOR202 (felzartamab) is an investigational monoclonal antibody designed to deplete CD38+ plasma cells, which are believed to drive Primary Membranous Nephropathy (PMN) through the production of anti-PLA2R (aPLA2R) autoantibodies.
Lead Product(s): Felzartamab
Therapeutic Area: Nephrology Product Name: MOR202
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
The proceedings for the development of felzartamab (MOR202), an anti-CD38 antibody, and HIB210, an anti-C5aR1 antibody. HI-Bio is testing felzartamab for MN and IgAN, with the potential to be the best-in-class therapy for autoantibody diseases.
Lead Product(s): Felzartamab
Therapeutic Area: Nephrology Product Name: MOR202
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
